Gil M. Labrucherie Purchases 3,718 Shares of Septerna, Inc. (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie bought 3,718 shares of Septerna stock in a transaction that occurred on Thursday, February 27th. The stock was bought at an average price of $5.85 per share, with a total value of $21,750.30. Following the purchase, the chief financial officer now owns 40,000 shares of the company’s stock, valued at $234,000. This trade represents a 10.25 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Septerna Price Performance

Shares of SEPN opened at $6.47 on Friday. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99. The business’s 50-day simple moving average is $16.08.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. RA Capital Management L.P. bought a new position in shares of Septerna in the fourth quarter valued at approximately $160,205,000. TRV GP V LLC bought a new position in shares of Septerna in the fourth quarter valued at approximately $142,337,000. TRV GP VI LLC bought a new position in shares of Septerna in the fourth quarter valued at approximately $72,191,000. Samsara BioCapital LLC bought a new position in shares of Septerna in the fourth quarter valued at approximately $63,399,000. Finally, Driehaus Capital Management LLC bought a new position in shares of Septerna in the fourth quarter valued at approximately $59,301,000.

Wall Street Analyst Weigh In

SEPN has been the subject of several research reports. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price for the company. TD Cowen started coverage on shares of Septerna in a research note on Tuesday, November 19th. They set a “buy” rating for the company. Wells Fargo & Company cut shares of Septerna from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $43.00 to $14.00 in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price target on shares of Septerna in a research note on Tuesday, February 11th.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.